Capstone Therapeutics ( (CAPS) ) has released a notification of late filing.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Capstone Therapeutics, under the name Capstone Holding Corp., has filed a Form 12b-25 to notify the delay of its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The primary reason for this delay is the company’s ongoing efforts to complete its financial statements and disclosures, which require additional time for review by its independent registered public accounting firm. Capstone anticipates filing the delayed report within five calendar days following the original due date. The company does not expect any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Matthew E. Lipman, the Chief Executive Officer, who assured ongoing compliance efforts.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
The overall stock score of 45 reflects significant financial challenges, including declining revenue, negative equity, and lack of profitability, which are the most impactful factors. Technical analysis indicates a bearish trend, and valuation metrics are unattractive due to negative earnings and no dividend yield. These factors collectively suggest a cautious outlook for Capstone Therapeutics.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Average Trading Volume: 2,491,857
Technical Sentiment Signal: Sell
Current Market Cap: $8.3M
For detailed information about CAPS stock, go to TipRanks’ Stock Analysis page.